Cure8 research brief
Measuring both how severe inflammation is and how much of the colon is affected could give a fuller picture of disease burden than current focal endoscopic scores. For patients with UC, that may affect risk assessment and treatment monitoring in the future.
Clinicians who perform and interpret endoscopy, researchers developing endoscopic scoring systems or AI tools, and patients interested in how endoscopic assessment may evolve.
This scoping review summarizes studies (2000–2025) that evaluated endoscopic indices for ulcerative colitis which incorporate disease extent, including conventional extent-based scores and AI-assisted assessments. The review found extent-integrated indices correlate better with biomarkers and histology than scores that focus only on the worst segment.
AI tools can automate mapping of inflammatory distribution and may boost reproducibility, but external validation and standardized methods are still limited.
At present, extent-based endoscopic assessment appears promising for more complete measurement of colonic inflammatory burden and for potential use in risk stratification and monitoring, but heterogeneity across studies and lack of large prospective multicenter validation are key limitations.
This record is a scoping review (abstract-level summary provided). Findings are synthesized narratively from heterogeneous studies; several AI approaches show promise but lack broad external validation. The review calls for standardized methods and multicenter prospective studies before routine clinical implementation.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
Distinguishing Crohn’s from ulcerative colitis can be hard and often requires invasive tests. A reliable blood test would speed diagnosis and help patients start the right treatments sooner. This study is an early step...
